News - Jul 4, 2026
Claude 4 Opus Lands — Anthropic's Priciest Model Yet
Anthropic has released Claude 4 Opus, the top tier of its Claude 4 model family, positioning it as its most capable model to date and its most expensive API offering. Pricing sits at $15 per million input tokens and $75 per million output tokens — a significant jump from Claude 3 Opus at $15 input and $75 output, though early benchmarks suggest meaningful gains on complex reasoning and coding tasks that may justify the cost for heavy users. The model shows measurable improvements on agentic tasks, multi-step reasoning, and long-context comprehension compared to Claude 3 Opus. It also introduces extended thinking capabilities natively, previously a bolt-on feature. Context window remains at 200K tokens. Who benefits: Enterprises running complex coding pipelines, legal or research teams processing dense documents, and developers building multi-step AI agents. Who gets hurt: Hobbyists and small teams will feel the cost immediately — at these rates, high-volume personal projects become genuinely expensive fast. Claude 4 Sonnet, the mid-tier option, remains the practical choice for most use cases at a fraction of the price. The honest read: Opus-tier models have always been Anthropic's showcase, not their workhorse — and that remains true here.
What changed
Claude 4 Opus introduces native extended thinking, improved performance on agentic and multi-step reasoning benchmarks, and maintains a 200K token context window. API pricing is $15 per million input tokens and $75 per million output tokens.
Who this affects
Enterprises and developers running complex, high-stakes pipelines where accuracy justifies cost. Small teams and hobbyists face steep bills for casual or experimental use.
Our take
Opus is a capability benchmark, not a daily driver — most users should stay on Sonnet and let enterprises foot the Opus bill.
Based on Anthropic's official Claude 4 release documentation and API pricing page. No affiliate relationship with Anthropic.
VerdictBloom is editorially independent. No company reviewed or approved this article before publication.